AxoGen (AXGN), a leading medical technology company focused on developing and commercializing innovative surgical solutions for peripheral nerve injuries, saw its stock surge 5.83% in after-hours trading on Monday. This significant move follows the company's strong performance, which has seen its shares hit a new 52-week high of $18.4 in the previous session.

The company's impressive run can be attributed to several key factors. First, AxoGen has consistently delivered positive earnings surprises, exceeding consensus estimates in each of the last four quarters. In its most recent earnings report on November 7, 2024, the company reported earnings per share (EPS) of $0.07, surpassing the consensus estimate of $0, while also beating revenue expectations by 3.5%.

Looking ahead, analysts are projecting robust growth for AxoGen. For the current fiscal year, the company is expected to post earnings of $0.31 per share on $185.2 million in revenues, representing significant year-over-year increases of 251.85% and 12.56%, respectively. This strong outlook, coupled with favorable valuation metrics and a Zacks Rank of #2 (Buy), suggests that AxoGen's stock could continue its upward trajectory.